Pfizer Pauses Experimental Gene Therapy Trial After Boy’s ‘Sudden’ Death

Pharmaceutical giant Pfizer Inc. has halted a study of an experimental gene therapy for muscular dystrophy after a child who received the treatment died due to cardiac arrest.

The New York City-headquartered drugmaker revealed the boy’s sudden death in a community letter shared by the nonprofit advocacy group Parent Project Muscular Dystrophy (PPMD).

The child—who was not identified by the company—received the investigational recombinant adeno-associated virus gene therapy known as fordadistrogene movaparvovec as part of Pfizer’s phase 2 “DAYLIGHT” study for Duchenne muscular dystrophy (DMD) in early 2023, the company said.

According to Pfizer, the “DAYLIGHT” study enrolled children between the ages of two and four.

The study has since concluded, Pfizer said.

Read Full Article Here